{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:30:55Z","timestamp":1776511855201,"version":"3.51.2"},"reference-count":186,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["EMIDDT"],"published-print":{"date-parts":[[2021,5]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Cardiovascular diseases are the leading cause of death in the modern world and dyslipidemia\nis one of the major risk factors. The current therapeutic strategies for cardiovascular diseases involve\nthe management of risk factors, especially dyslipidemia and hypertension. Recently, the updated\nguidelines of dyslipidemia management were presented, and the newest data were included in terms of\ndiagnosis, imaging, and treatment. In this targeted literature review, the researchers presented the most\nrecent evidence on dyslipidemia management by including the current therapeutic goals for it. In addition,\nthe novel diagnostic tools based on theranostics are shown. Finally, the future perspectives on\ntreatment based on novel drug delivery systems and their potential to be used in clinical trials were also\nanalyzed. It should be noted that dyslipidemia management can be achieved by the strict lifestyle\nchange, i.e., by adopting a healthy life, and choosing the most suitable medication. This review can\nhelp medical professionals as well as specialists of other sciences to update their knowledge on dyslipidemia\nmanagement, which can lead to better therapeutic outcomes and newer drug developments.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871530320666200810144004","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T07:41:02Z","timestamp":1597131662000},"page":"815-834","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Dyslipidemia Management in 2020: An Update on Diagnosis and Therapeutic Perspectives"],"prefix":"10.2174","volume":"21","author":[{"given":"Ioannis D.","family":"Karantas","sequence":"first","affiliation":[{"name":"Nicosia General Hospital, Nicosia,Cyprus"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet E.","family":"Okur","sequence":"additional","affiliation":[{"name":"University of Health Sciences, Faculty of Pharmacy, Department of Pharmacology, Istanbul,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neslihan \u00dc.","family":"Okur","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Health Sciences, Istanbul,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panoraia I.","family":"Siafaka","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Health Sciences, Istanbul,Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","volume":"37","author":"Townsend N.","year":"2016","unstructured":"Townsend N.; Wilson L.; Bhatnagar P.; Wickramasinghe K.; Rayner M.; Nichols M.; Cardiovascular disease in Europe: epidemiological update 2016. Eur Heart J 2016,37(42),3232-3245","journal-title":"Eur Heart J"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.2174\/1381612823666170927123454","volume":"23","author":"Okur M.E.","year":"2017","unstructured":"Okur M.E.; Karantas I.D.; Okur N.U.; Siafaka P.I.; Hypertension in 2017: Update in Treatment and Pharmaceutical Innovations. Curr Pharm Des 2017,23(44),6795-6814","journal-title":"Curr Pharm Des"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"61","DOI":"10.23893\/1307-2080.APS.0555","volume":"55","author":"Okur M.E.","year":"2017","unstructured":"Okur M.E.; Karantas I.D.; Siafaka P.I.; Diabetes Mellitus: A Review on Pathophysiology, Current Status of Oral Medications and Future Perspectives. Acta Pharm Sci 2017,55(1),61-82","journal-title":"Acta Pharm Sci"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/VHRM.S168946","volume":"15","author":"Carbone S.","year":"2019","unstructured":"Carbone S.; Canada J.M.; Billingsley H.E.; Siddiqui M.S.; Elagizi A.; Lavie C.J.; Obesity paradox in cardiovascular disease: where do we stand? Vasc Health Risk Manag 2019,15,89-100","journal-title":"Vasc Health Risk Manag"},{"key":"ref=5","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012924","volume":"8","author":"Gidding S.S.","year":"2019","unstructured":"Gidding S.S.; Allen N.B.; Cholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong Problem. J Am Heart Assoc 2019,8(11)","journal-title":"J Am Heart Assoc"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1038\/s41572-019-0106-z","volume":"5","author":"Libby P.","year":"2019","unstructured":"Libby P.; Buring J.E.; Badimon L.; Hansson G.K.; Deanfield J.; Bittencourt M.S.; Tokg\u00f6zo\u011flu L.; Lewis E.F.; Atherosclerosis. Nat Rev Dis Primers 2019,5(1),56","journal-title":"Nat Rev Dis Primers"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1194\/jlr.E033407","volume":"53","author":"Feingold K.R.","year":"2012","unstructured":"Feingold K.R.; Grunfeld C.; Lipids: a key player in the battle between the host and microorganisms. J Lipid Res 2012,53(12),2487-2489","journal-title":"J Lipid Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/MOL.0000000000000297","volume":"27","author":"Olivecrona G.","year":"2016","unstructured":"Olivecrona G.; Role of lipoprotein lipase in lipid metabolism. Curr Opin Lipidol 2016,27(3),233-241","journal-title":"Curr Opin Lipidol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1080\/00498250802007930","volume":"38","author":"Kidambi S.","year":"2008","unstructured":"Kidambi S.; Patel S.B.; Cholesterol and non-cholesterol sterol transporters: ABCG5, ABCG8 and NPC1L1: a review. Xenobiotica 2008,38(7-8),1119-1139","journal-title":"Xenobiotica"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.12.027","volume":"211","author":"Dallinga-Thie G.M.","year":"2010","unstructured":"Dallinga-Thie G.M.; Franssen R.; Mooij H.L.; Visser M.E.; Hassing H.C.; Peelman F.; Kastelein J.J.P.; P\u00e9terfy M.; Nieuwdorp M.; The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. Atherosclerosis 2010,211(1),1-8","journal-title":"Atherosclerosis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.atherosclerosissup.2010.03.003","volume":"11","author":"Kindel T.","year":"2010","unstructured":"Kindel T.; Lee D.M.; Tso P.; The mechanism of the formation and secretion of chylomicrons. Atheroscler Suppl 2010,11(1),11-16","journal-title":"Atheroscler Suppl"},{"key":"ref=12","first-page":"153","author":"Cox R.","year":"1990","unstructured":"Cox R.; Garc\u00eda-Palmieri M.;  Clinical Methods: The History, Physical, and Laboratory Examinations 1990,153-160","journal-title":"Clinical Methods: The History, Physical, and Laboratory Examinations"},{"key":"ref=13","author":"Wengrofsky P.","year":"2019","unstructured":"Wengrofsky P.;  Dyslipidemia; IntechOpen 2019","journal-title":"Dyslipidemia; IntechOpen"},{"key":"ref=14","first-page":"434","volume":"106","author":"Garc\u00eda-Giustiniani D.","year":"2016","unstructured":"Garc\u00eda-Giustiniani D.; Stein R.; Genetics of Dyslipidemia. Arq Bras Cardiol 2016,106(5),434-438","journal-title":"Arq Bras Cardiol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"13455","DOI":"10.3390\/ijerph121013455","volume":"12","author":"Qi L.","year":"2015","unstructured":"Qi L.; Ding X.; Tang W.; Li Q.; Mao D.; Wang Y.; Prevalence and Risk Factors Associated with Dyslipidemia in Chongqing, China. Int J Environ Res Public Health 2015,12(10),13455-13465","journal-title":"Int J Environ Res Public Health"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.jacl.2013.12.011","volume":"8","author":"Bayram F.","year":"2014","unstructured":"Bayram F.; Kocer D.; Gundogan K.; Kaya A.; Demir O.; Coskun R.; Sabuncu T.; Karaman A.; Cesur M.; Rizzo M.; Toth P.P.; Gedik V.; Prevalence of dyslipidemia and associated risk factors in Turkish adults. J Clin Lipidol 2014,8(2),206-216","journal-title":"J Clin Lipidol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/pgmj.2004.025601","volume":"81","author":"Kolovou G.D.","year":"2005","unstructured":"Kolovou G.D.; Anagnostopoulou K.K.; Cokkinos D.V.; Pathophysiology of dyslipidaemia in the metabolic syndrome. Postgrad Med J 2005,81(956),358-366","journal-title":"Postgrad Med J"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1177\/1559827609334518","volume":"3","author":"Leon A.S.","year":"2009","unstructured":"Leon A.S.; Bronas U.G.; Dyslipidemia and Risk of Coronary Heart Disease: Role of Lifestyle Approaches for Its Management. Am J Lifestyle Med 2009,3(4),257-273","journal-title":"Am J Lifestyle Med"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.jnutbio.2013.02.009","volume":"24","author":"Ruiz-N\u00fa\u00f1ez B.","year":"2013","unstructured":"Ruiz-N\u00fa\u00f1ez B.; Pruimboom L.; Dijck-Brouwer D.A.J.; Muskiet F.A.J.; Lifestyle and nutritional imbalances associated with Western diseases: causes and consequences of chronic systemic low-grade inflammation in an evolutionary context. J Nutr Biochem 2013,24(7),1183-1201","journal-title":"J Nutr Biochem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"758","DOI":"10.4065\/83.7.758","volume":"83","author":"Becker D.J.","year":"2008","unstructured":"Becker D.J.; Gordon R.Y.; Morris P.B.; Yorko J.; Gordon Y.J.; Li M.; Iqbal N.; Simvastatin vs therapeutic lifestyle changes and supplements: randomized primary prevention trial. Mayo Clin Proc 2008,83(7),758-764","journal-title":"Mayo Clin Proc"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5534\/wjmh.2015.33.3.167","volume":"33","author":"Mohammadbeigi A.","year":"2015","unstructured":"Mohammadbeigi A.; Moshiri E.; Mohammadsalehi N.; Ansari H.; Ahmadi A.; Dyslipidemia Prevalence in Iranian Adult Men: The Impact of Population-Based Screening on the Detection of Undiagnosed Patients. World J Mens Health 2015,33(3),167-173","journal-title":"World J Mens Health"},{"key":"ref=22","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/943162","volume":"2014","author":"Kaur J.","year":"2014","unstructured":"Kaur J.; A comprehensive review on metabolic syndrome. Cardiol Res Pract 2014,2014","journal-title":"Cardiol Res Pract"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.3904\/kjim.2019.188","volume":"34","author":"Rhee E-J.","year":"2019","unstructured":"Rhee E-J.; Kim H.C.; Kim J.H.; Lee E.Y.; Kim B.J.; Kim E.M.; Song Y.; Lim J.H.; Kim H.J.; Choi S.; Moon M.K.; Na J.O.; Park K-Y.; Oh M.S.; Han S.Y.; Noh J.; Yi K.H.; Lee S-H.; Hong S-C.; Jeong I-K.; 2018 Guidelines for the management of dyslipidemia. Korean J Intern Med (Korean Assoc Intern Med) 2019,34(4),723-771","journal-title":"Korean J Intern Med (Korean Assoc Intern Med)"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"Mach F.","year":"2020","unstructured":"Mach F.; Baigent C.; Catapano A.L.; Koskinas K.C.; Casula M.; Badimon L.; Chapman M.J.; De Backer G.G.; Delgado V.; Ference B.A.; Graham I.M.; Halliday A.; Landmesser U.; Mihaylova B.; Pedersen T.R.; Riccardi G.; Richter D.J.; Sabatine M.S.; Taskinen M-R.; Tokgozoglu L.; Wiklund O.; Mueller C.; Drexel H.; Aboyans V.; Corsini A.; Doehner W.; Farnier M.; Gigante B.; Kayikcioglu M.; Krstacic G.; Lambrinou E.; Lewis B.S.; Masip J.; Moulin P.; Petersen S.; Petronio A.S.; Piepoli M.F.; Pint\u00f3 X.; R\u00e4ber L.; Ray K.K.; Reiner \u017d.; Riesen W.F.; Roffi M.; Schmid J-P.; Shlyakhto E.; Simpson I.A.; Stroes E.; Sudano I.; Tselepis A.D.; Viigimaa M.; Vindis C.; Vonbank A.; Vrablik M.; Vrsalovic M.; Zamorano J.L.; Collet J-P.; Koskinas K.C.; Casula M.; Badimon L.; John Chapman M.; De Backer G.G.; Delgado V.; Ference B.A.; Graham I.M.; Halliday A.; Landmesser U.; Mihaylova B.; Pedersen T.R.; Riccardi G.; Richter D.J.; Sabatine M.S.; Taskinen M-R.; Tokgozoglu L.; Wiklund O.; Windecker S.; Aboyans V.; Baigent C.; Collet J-P.; Dean V.; Delgado V.; Fitzsimons D.; Gale C.P.; Grobbee D.; Halvorsen S.; Hindricks G.; Iung B.; J\u00fcni P.; Katus H.A.; Landmesser U.; Leclercq C.; Lettino M.; Lewis B.S.; Merkely B.; Mueller C.; Petersen S.; Petronio A.S.; Richter D.J.; Roffi M.; Shlyakhto E.; Simpson I.A.; Sousa-Uva M.; Touyz R.M.; Nibouche D.; Zelveian P.H.; Siostrzonek P.; Najafov R.; van de Borne P.; Pojskic B.; Postadzhiyan A.; Kypris L.; \u0160pinar J.; Larsen M.L.; Eldin H.S.; Viigimaa M.; Strandberg T.E.; Ferri\u00e8res J.; Agladze R.; Laufs U.; Rallidis L.; Bajnok L.; Gudj\u00f3nsson T.; Maher V.; Henkin Y.; Gulizia M.M.; Mussagaliyeva A.; Bajraktari G.; Kerimkulova A.; Latkovskis G.; Hamoui O.; Slapikas R.; Visser L.; Dingli P.; Ivanov V.; Boskovic A.; Nazzi M.; Visseren F.; Mitevska I.; Retterst\u00f8l K.; Jankowski P.; Fontes-Carvalho R.; Gaita D.; Ezhov M.; Foscoli M.; Giga V.; Pella D.; Fras Z.; de Isla L.P.; Hagstr\u00f6m E.; Lehmann R.; Abid L.; Ozdogan O.; Mitchenko O.; Patel R.S.; 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J ESC Scientific Document Group2020,41(1),111-188","journal-title":"Eur Heart J"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s00018-003-3262-x","volume":"61","author":"Gustafsson M.","year":"2004","unstructured":"Gustafsson M.; Flood C.; Jirholt P.; Bor\u00e9n J.; Retention of atherogenic lipoproteins in atherogenesis. Cell Mol Life Sci 2004,61(1),4-9","journal-title":"Cell Mol Life Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"Tsimikas S.","year":"2020","unstructured":"Tsimikas S.; Karwatowska-Prokopczuk E.; Gouni-Berthold I.; Tardif J-C.; Baum S.J.; Steinhagen-Thiessen E.; Shapiro M.D.; Stroes E.S.; Moriarty P.M.; Nordestgaard B.G.; Xia S.; Guerriero J.; Viney N.J.; O\u2019Dea L.; Witztum J.L.; Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. N Engl J Med AKCEA-APO(a)-LRx Study Investigators2020,382(3),244-255","journal-title":"N Engl J Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11883-019-0803-9","volume":"21","author":"Stulnig T.M.","year":"2019","unstructured":"Stulnig T.M.; Morozzi C.; Reindl-Schwaighofer R.; Stefanutti C.; Looking at Lp(a) and Related Cardiovascular Risk: from Scientific Evidence and Clinical Practice. Curr Atheroscler Rep 2019,21(10),37","journal-title":"Curr Atheroscler Rep"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/713609328","volume":"40","author":"Lippi G.","year":"2003","unstructured":"Lippi G.; Guidi G.; Lipoprotein(a): an emerging cardiovascular risk factor. Crit Rev Clin Lab Sci 2003,40(1),1-42","journal-title":"Crit Rev Clin Lab Sci"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","volume":"139","author":"O\u2019Donoghue M.L.","year":"2019","unstructured":"O\u2019Donoghue M.L.; Fazio S.; Giugliano R.P.; Stroes E.S.G.; Kanevsky E.; Gouni-Berthold I.; Im K.; Lira Pineda A.; Wasserman S.M.; \u010ce\u0161ka R.; Ezhov M.V.; Jukema J.W.; Jensen H.K.; Tokg\u00f6zo\u011flu S.L.; Mach F.; Huber K.; Sever P.S.; Keech A.C.; Pedersen T.R.; Sabatine M.S.; Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk. Circulation 2019,139(12),1483-1492","journal-title":"Circulation"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1016\/S0140-6736(15)61252-1","volume":"386","author":"Tsimikas S.","year":"2015","unstructured":"Tsimikas S.; Viney N.J.; Hughes S.G.; Singleton W.; Graham M.J.; Baker B.F.; Burkey J.L.; Yang Q.; Marcovina S.M.; Geary R.S.; Crooke R.M.; Witztum J.L.; Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015,386(10002),1472-1483","journal-title":"Lancet"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","volume":"38","author":"Ference B.A.","year":"2017","unstructured":"Ference B.A.; Ginsberg H.N.; Graham I.; Ray K.K.; Packard C.J.; Bruckert E.; Hegele R.A.; Krauss R.M.; Raal F.J.; Schunkert H.; Watts G.F.; Bor\u00e9n J.; Fazio S.; Horton J.D.; Masana L.; Nicholls S.J.; Nordestgaard B.G.; van de Sluis B.; Taskinen M-R.; Tokg\u00f6zoglu L.; Landmesser U.; Laufs U.; Wiklund O.; Stock J.K.; Chapman M.J.; Catapano A.L.; Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017,38(32),2459-2472","journal-title":"Eur Heart J"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1161\/hc0902.104353","volume":"105","author":"Libby P.","year":"2002","unstructured":"Libby P.; Ridker P.M.; Maseri A.; Inflammation and atherosclerosis. Circulation 2002,105(9),1135-1143","journal-title":"Circulation"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","volume":"32","author":"Libby P.","year":"2012","unstructured":"Libby P.; Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012,32(9),2045-2051","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","volume":"145","author":"Moore K.J.","year":"2011","unstructured":"Moore K.J.; Tabas I.; Macrophages in the pathogenesis of atherosclerosis. Cell 2011,145(3),341-355","journal-title":"Cell"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/nri3520","volume":"13","author":"Moore K.J.","year":"2013","unstructured":"Moore K.J.; Sheedy F.J.; Fisher E.A.; Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013,13(10),709-721","journal-title":"Nat Rev Immunol"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/1538574416628654","volume":"50","author":"Helkin A.","year":"2016","unstructured":"Helkin A.; Stein J.J.; Lin S.; Siddiqui S.; Maier K.G.; Gahtan V.; Dyslipidemia Part 1--Review of Lipid Metabolism and Vascular Cell Physiology. Vasc Endovascular Surg 2016,50(2),107-118","journal-title":"Vasc Endovascular Surg"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5507\/bp.2014.016","volume":"158","author":"Zak A.","year":"2014","unstructured":"Zak A.; Zeman M.; Slaby A.; Vecka M.; Xanthomas: clinical and pathophysiological relations. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014,158(2),181-188","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1503\/cmaj.130148","volume":"185","author":"Ladizinski B.","year":"2013","unstructured":"Ladizinski B.; Lee K.C.; Eruptive xanthomas in a patient with severe hypertriglyceridemia and type 2 diabetes. CMAJ 2013,185(18),1600-1600","journal-title":"CMAJ"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1177\/2050640618755002","volume":"6","author":"de Pretis N.","year":"2018","unstructured":"de Pretis N.; Amodio A.; Frulloni L.; Hypertriglyceridemic pancreatitis: Epidemiology, pathophysiology and clinical management. United European Gastroenterol J 2018,6(5),649-655","journal-title":"United European Gastroenterol J"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.6224","volume":"137","author":"Wong S.","year":"2019","unstructured":"Wong S.; Shields R.; Silva R.A.; Lipemia Retinalis in a Woman With Hypertriglyceridemia. JAMA Ophthalmol 2019,137(11)","journal-title":"JAMA Ophthalmol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jacl.2010.11.004","volume":"5","author":"Tremblay K.","year":"2011","unstructured":"Tremblay K.; M\u00e9thot J.; Brisson D.; Gaudet D.; Etiology and risk of lactescent plasma and severe hypertriglyceridemia. J Clin Lipidol 2011,5(1),37-44","journal-title":"J Clin Lipidol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1186\/1752-1947-6-412","volume":"6","author":"Inokuchi R.","year":"2012","unstructured":"Inokuchi R.; Matsumoto A.; Azihara R.; Sato H.; Kumada Y.; Yokoyama H.; Okada M.; Ishida T.; Nakamura K.; Nakajima S.; Yahagi N.; Shinohara K.; Hypertriglyceridemia as a possible cause of coma: a case report. J Med Case Reports 2012,6(1),412","journal-title":"J Med Case Reports"},{"key":"ref=43","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/6273196","volume":"2019","author":"Toor A.","year":"2019","unstructured":"Toor A.; Toor A.; Khalighi K.; Krishnamurthy M.; Triglyceride Levels Greater Than 10,000 mg\/dL in a 49-Year-Old Female without Evidence of Pancreatitis. Case Rep Endocrinol 2019,2019","journal-title":"Case Rep Endocrinol"},{"key":"ref=44","first-page":"104","volume":"01","author":"Avasia A.R.","year":"2015","unstructured":"Avasia A.R.; Rodziewicz N.; Bhushan S.; Singh N.; Milky Serum in Hypertriglyceridemia: Clinical Image. Arch. Case Reports Clin Med 2015,01(01),104","journal-title":"Case Reports Clin Med"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1093\/ije\/dyz099","volume":"49","author":"Taddei C.","year":"2020","unstructured":"Taddei C.; Jackson R.; Zhou B.; Bixby H.; Danaei G.; Di Cesare M.; Kuulasmaa K.; Hajifathalian K.; Bentham J.; Bennett J.E.; Aekplakorn W.; Cifkova R.; Dallongeville J.; DeBacquer D.; Giampaoli S.; Gudnason V.; Khang Y-H.; Laatikainen T.; Mann J.; Marques-Vidal P.; Mensah G.A.; M\u00fcller-Nurasyid M.; Ninomiya T.; Petkeviciene J.; Rodr\u00edguez-Artalejo F.; Servais J.; S\u00f6derberg S.; Stavreski B.; Wilsgaard T.; Zdrojewski T.; Zhao D.; Stevens G.A.; Savin S.; Cowan M.J.; Riley L.M.; Ezzati M.; Adams R.J.; Aekplakorn W.; Ahrens W.; Amouyel P.; Amuzu A.; Anderssen S.A.; Ariansen I.; Arveiler D.; Aspelund T.; Auvinen J.; Avdicov\u00e1 M.; Banach M.; Bandosz P.; Banegas J.R.; Barbagallo C.M.; Bata I.; Baur L.A.; Beaglehole R.; Bennett J.E.; Bernotiene G.; Bi Y.; Bienek A.; Bj\u00f6rkelund C.; Bo S.; Boehm B.O.; Bonaccio M.; Bongard V.; Borchini R.; Borghs H.; Breckenkamp J.; Brenner H.; Bruno G.; Busch M.A.; Cabrera de Le\u00f3n A.; Capuano V.; Casanueva F.F.; Casas J-P.; Caserta C.A.; Censi L.; Chen F.; Chen S.; Chirlaque M-D.; Cho B.; Cho Y.; Chudek J.; Cifkova R.; Claessens F.; Clarke J.; Clays E.; Cooper C.; Costanzo S.; Cottel D.; Cowell C.; Crujeiras A.B.; Cui L.; D\u2019Arrigo G.; Dallongeville J.; Dauchet L.; De Backer G.; De Bacquer D.; de Gaetano G.; De Henauw S.; De Smedt D.; Dennison E.; Deschamps V.; DiCastelnuovo A.; Dobson A.J.; Donfrancesco C.; D\u00f6ring A.; Drygas W.; Du Y.; Dziankowska-Zaborszczyk E.; Eggertsen R.; Ekelund U.; Elosua R.; Eriksson J.G.; Evans A.; Faeh D.; Felix-Redondo F.J.; Fern\u00e1ndez-Berg\u00e9s D.; Ferrari M.; Ferrieres J.; Finn J.D.; Forslund A-S.; Forsner M.; Frontera G.; Fujita Y.; Gaciong Z.; Galvano F.; Gao J.; Garcia-de-la-Hera M.; Garnett S.P.; Gaspoz J-M.; Gasull M.; Gates L.; Giampaoli S.; Gianfagna F.; Gill T.K.; Giovannelli J.; Goltzman D.; National trends in total cholesterol obscure heterogeneous changes in HDL and non-HDL cholesterol and total-to-HDL cholesterol ratio: a pooled analysis of 458 population-based studies in Asian and Western countries. Int J Epidemiol NCD Risk Factor Collaboration (NCD-RisC)2020,49(1),173-192","journal-title":"Int J Epidemiol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"C6","DOI":"10.1016\/j.jacc.2013.08.025","volume":"62","author":"O\u011fuz A.","year":"2013","unstructured":"O\u011fuz A.; G\u00fcle\u00e7 S.; Temizhan A.; Altunta\u015f Y.; Kar\u015f\u0131da\u011f K.; Akal\u0131n A.A.; T\u00fcmerdem \u00c7al\u0131k B.; \u0130mery\u00fcz N.; The Frequency of Dyslipidemia in Adults in Turkey. J Am Coll Cardiol 2013,62(18),C6","journal-title":"J Am Coll Cardiol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"556","DOI":"10.5543\/tkda.2018.23450","volume":"46","author":"Kay\u0131k\u00e7\u0131o\u011flu M.","year":"2018","unstructured":"Kay\u0131k\u00e7\u0131o\u011flu M.; Systematic Review and Meta-Analysis of Epidemiological Studies for Cardiovascular Risk Factors Conducted in Turkey: Prevelance of Dislipidemias and Lipid Data. Turk Kardiyol. Dern. Arsivi-Archives Turkish Soc. Cardiol 2018,46(7),556-574","journal-title":"Cardiol"},{"key":"ref=48","first-page":"217","volume":"55","author":"Elisaf M.","year":"2014","unstructured":"Elisaf M.; Tzouvelekis E.; Nikas N.; Primary prevention of cardiovascular disease in Greece: Greek results of the EURIKA study. Hellenic J Cardiol Greek EURIKA Investigators2014,55(3),217-226","journal-title":"Hellenic J Cardiol"},{"key":"ref=49","first-page":"442","volume":"55","author":"Sbarouni E.","year":"2014","unstructured":"Sbarouni E.; Voudris V.; Georgiadou P.; Hamilos M.; Steg P.G.; Fox K.M.; Greenlaw N.; Ferrari R.; Vardas P.E.; Clinical presentation and management of stable coronary artery disease: insights from the international prospective CLARIFY registry - results from the Greek national cohort. Hellenic J Cardiol 2014,55(6),442-447","journal-title":"Hellenic J Cardiol"},{"key":"ref=50","first-page":"33","volume":"53","author":"Andrikopoulos G.","year":"2012","unstructured":"Andrikopoulos G.; Tzeis S.; Mantas I.; Olympios C.; Kitsiou A.; Kartalis A.; Kranidis A.; Tsaknakis T.; Richter D.; Pras A.; Pipilis A.; Lampropoulos S.; Oikonomou K.; Gotsis A.; Anastasiou-Nana M.; Triposkiadis F.; Goudevenos J.; Theodorakis G.; Vardas P.; Epidemiological characteristics and in-hospital management of acute coronary syndrome patients in Greece: results from the TARGET study. Hellenic J Cardiol 2012,53(1),33-40","journal-title":"Hellenic J Cardiol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1161\/01.cir.0000437738.63853.7a","volume":"129","author":"Stone N.J.","year":"2014","unstructured":"Stone N.J.; Robinson J.G.; Lichtenstein A.H.; Bairey Merz C.N.; Blum C.B.; Eckel R.H.; Goldberg A.C.; Gordon D.; Levy D.; Lloyd-Jones D.M.; McBride P.; Schwartz J.S.; Shero S.T.; Smith S.C.; Watson K.; Wilson P.W.F.; Eddleman K.M.; Jarrett N.M.; LaBresh K.; Nevo L.; Wnek J.; Anderson J.L.; Halperin J.L.; Albert N.M.; Bozkurt B.; Brindis R.G.; Curtis L.H.; DeMets D.; Hochman J.S.; Kovacs R.J.; Ohman E.M.; Pressler S.J.; Sellke F.W.; Shen W.K.; Smith S.C.; Tomaselli G.F.; 2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation American College of Cardiology\/American Heart Association Task Force on Practice Guidelines2014,129(25)(Suppl. 2),S1-S45","journal-title":"Circulation"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/EP171764.APPGL","volume":"23","author":"Jellinger P.S.","year":"2017","unstructured":"Jellinger P.S.; Handelsman Y.; Rosenblit P.D.; Bloomgarden Z.T.; Fonseca V.A.; Garber A.J.; Grunberger G.; Guerin C.K.; Bell D.S.H.; Mechanick J.I.; Pessah-Pollack R.; Wyne K.; Smith D.; Brinton E.A.; Fazio S.; Davidson M.; American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract 2017,23(Suppl. 2),1-87","journal-title":"Endocr Pract"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","volume":"376","author":"Sabatine M.S.","year":"2017","unstructured":"Sabatine M.S.; Giugliano R.P.; Keech A.C.; Honarpour N.; Wiviott S.D.; Murphy S.A.; Kuder J.F.; Wang H.; Liu T.; Wasserman S.M.; Sever P.S.; Pedersen T.R.; Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med FOURIER Steering Committee and Investigators2017,376(18),1713-1722","journal-title":"N Engl J Med"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","volume":"372","author":"Cannon C.P.","year":"2015","unstructured":"Cannon C.P.; Blazing M.A.; Giugliano R.P.; McCagg A.; White J.A.; Theroux P.; Darius H.; Lewis B.S.; Ophuis T.O.; Jukema J.W.; De Ferrari G.M.; Ruzyllo W.; De Lucca P.; Im K.; Bohula E.A.; Reist C.; Wiviott S.D.; Tershakovec A.M.; Musliner T.A.; Braunwald E.; Califf R.M.; Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes. N Engl J Med IMPROVE-IT Investigators2015,372(25),2387-2397","journal-title":"N Engl J Med"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","volume":"379","author":"Schwartz G.G.","year":"2018","unstructured":"Schwartz G.G.; Steg P.G.; Szarek M.; Bhatt D.L.; Bittner V.A.; Diaz R.; Edelberg J.M.; Goodman S.G.; Hanotin C.; Harrington R.A.; Jukema J.W.; Lecorps G.; Mahaffey K.W.; Moryusef A.; Pordy R.; Quintero K.; Roe M.T.; Sasiela W.J.; Tamby J-F.; Tricoci P.; White H.D.; Zeiher A.M.; Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med ODYSSEY OUTCOMES Committees and Investigators2018,379(22),2097-2107","journal-title":"N Engl J Med"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.ihj.2017.01.015","volume":"69","author":"Garg N.","year":"2017","unstructured":"Garg N.; Muduli S.K.; Kapoor A.; Tewari S.; Kumar S.; Khanna R.; Goel P.K.; Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart J 2017,69(4),458-463","journal-title":"Indian Heart J"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.clinbiochem.2017.11.007","volume":"52","author":"Cartier L-J.","year":"2018","unstructured":"Cartier L-J.; Collins C.; Lagac\u00e9 M.; Douville P.; Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. Clin Biochem 2018,52,61-66","journal-title":"Clin Biochem"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"Catapano A.L.","year":"2016","unstructured":"Catapano A.L.; Graham I.; De Backer G.; Wiklund O.; Chapman M.J.; Drexel H.; Hoes A.W.; Jennings C.S.; Landmesser U.; Pedersen T.R.; Reiner \u017d.; Riccardi G.; Taskinen M-R.; Tokgozoglu L.; Verschuren W.M.M.; Vlachopoulos C.; Wood D.A.; Zamorano J.L.; Cooney M.T.; 2016 ESC\/EAS Guidelines for the Management of Dyslipidaemias. Eur Heart J ESC Scientific Document Group2016,37(39),2999-3058","journal-title":"Eur Heart J"},{"key":"ref=59","author":"Hennekens C.H.","unstructured":"Hennekens C.H.; Lopez-Sendon J.; Overview of the prevention of cardiovascular disease events in those with established disease (secondary prevention) or at high risk Available at:"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1001\/jama.2016.16650","volume":"316","author":"Jin J.","year":"2016","unstructured":"Jin J.; Lipid Disorders: Screening and Treatment. JAMA 2016,316(19),2056","journal-title":"JAMA"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jacc.2009.07.057","volume":"55","author":"Arsenault B.J.","year":"2009","unstructured":"Arsenault B.J.; Rana J.S.; Stroes E.S.G.; Despr\u00e9s J-P.; Shah P.K.; Kastelein J.J.P.; Wareham N.J.; Boekholdt S.M.; Khaw K-T.; Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol\/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009,55(1),35-41","journal-title":"J Am Coll Cardiol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1161\/CIRCULATIONAHA.119.038989","volume":"139","author":"Thanassoulis G.","year":"2019","unstructured":"Thanassoulis G.; Screening for High Lipoprotein(a). Circulation 2019,139(12),1493-1496","journal-title":"Circulation"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.jacl.2017.07.005","volume":"11","author":"Weiss M.C.","year":"2017","unstructured":"Weiss M.C.; Berger J.S.; Gianos E.; Fisher E.; Schwartzbard A.; Underberg J.; Weintraub H.; Lipoprotein(a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention. J Clin Lipidol 2017,11(5),1177-1180","journal-title":"J Clin Lipidol"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s13668-013-0065-z","volume":"2","author":"Pollin T.I.","year":"2013","unstructured":"Pollin T.I.; Quartuccio M.; What We Know About Diet, Genes, and Dyslipidemia: Is There Potential for Translation? Curr Nutr Rep 2013,2(4),236-242","journal-title":"Curr Nutr Rep"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1093\/ajcn\/nqx013","volume":"107","author":"Drouin-Chartier J-P.","year":"2018","unstructured":"Drouin-Chartier J-P.; Tremblay A.J.; L\u00e9pine M-C.; Lemelin V.; Lamarche B.; Couture P.; Substitution of dietary \u03c9-6 polyunsaturated fatty acids for saturated fatty acids decreases LDL apolipoprotein B-100 production rate in men with dyslipidemia associated with insulin resistance: a randomized controlled trial. Am J Clin Nutr 2018,107(1),26-34","journal-title":"Am J Clin Nutr"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11886-016-0744-7","volume":"18","author":"Riccardi G.","year":"2016","unstructured":"Riccardi G.; Vaccaro O.; Costabile G.; Rivellese A.A.; How Well Can We Control Dyslipidemias Through Lifestyle Modifications? Curr Cardiol Rep 2016,18(7),66","journal-title":"Curr Cardiol Rep"},{"key":"ref=67","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.118.008953","volume":"7","author":"Handelsman Y.","year":"2018","unstructured":"Handelsman Y.; Lepor N.E.; PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review. J Am Heart Assoc 2018,7(13)","journal-title":"J Am Heart Assoc"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/03007995.2018.1532885","volume":"35","author":"Tai M-H.","year":"2019","unstructured":"Tai M-H.; Shepherd J.; Bailey H.; Williams N.; Hatz M.; Campos Tapias I.; Catterick D.; Worth G.; Real-world treatment patterns of PCSK9 inhibitors among patients with dyslipidemia in Germany, Spain, and the United Kingdom. Curr Med Res Opin 2019,35(5),829-835","journal-title":"Curr Med Res Opin"},{"key":"ref=69","unstructured":"EMA report EMA https:\/\/www.ema.europa.eu\/en\/","journal-title":"EMA report"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.pcad.2016.08.003","volume":"59","author":"Agrawal N.","year":"2016","unstructured":"Agrawal N.; Freitas Corradi P.; Gumaste N.; Goldberg I.J.; Triglyceride Treatment in the Age of Cholesterol Reduction. Prog Cardiovasc Dis 2016,59(2),107-118","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s11883-005-0072-7","volume":"7","author":"Ansell B.J.","year":"2005","unstructured":"Ansell B.J.; Rationale for Combination Therapy with Statin Drugs in the Treatment of Dyslipidemia. Curr Atheroscler Rep 2005,7(1),29-33","journal-title":"Curr Atheroscler Rep"},{"key":"ref=72","doi-asserted-by":"crossref","first-page":"47B","DOI":"10.1016\/S0002-9149(98)00038-1","volume":"Vol. 81","author":"Garg A.","year":"1998","unstructured":"Garg A.;  American Journal of Cardiology 1998,Vol. 81,47B-51B","journal-title":"American Journal of Cardiology"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1210\/jc.2005-2084","volume":"91","author":"Ginsberg H.N.","year":"2006","unstructured":"Ginsberg H.N.; REVIEW: Efficacy and mechanisms of action of statins in the treatment of diabetic dyslipidemia. J Clin Endocrinol Metab 2006,91(2),383-392","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"324","DOI":"10.5935\/abc.20150005","volume":"104","author":"Bonfim M.R.","year":"2015","unstructured":"Bonfim M.R.; Oliveira A.S.B.; do Amaral S.L.; Monteiro H.L.; Treatment of dyslipidemia with statins and physical exercises: recent findings of skeletal muscle responses. Arq Bras Cardiol 2015,104(4),324-331","journal-title":"Arq Bras Cardiol"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"23","DOI":"10.17925\/USE.2011.07.01.23","volume":"7","author":"Fazio S.","year":"2011","unstructured":"Fazio S.; The Role of Statin Therapy in Primary Hyperlipidemia and Mixed Dyslipidemia. US Endocrinol 2011,7(1),23-29","journal-title":"US Endocrinol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1016\/j.cpcardiol.2006.03.001","volume":"31","author":"Gau G.T.","year":"2006","unstructured":"Gau G.T.; Wright R.S.; Pathophysiology, diagnosis, and management of dyslipidemia. Curr Probl Cardiol 2006,31(7),445-486","journal-title":"Curr Probl Cardiol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1067\/mhj.2003.70","volume":"145","author":"Clark L.T.","year":"2003","unstructured":"Clark L.T.; Treating dyslipidemia with statins: the risk-benefit profile. Am Heart J 2003,145(3),387-396","journal-title":"Am Heart J"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1582-4934.2001.tb00172.x","volume":"5","author":"Stancu C.","year":"2001","unstructured":"Stancu C.; Sima A.; Statins: mechanism of action and effects. J Cell Mol Med 2001,5(4),378-387","journal-title":"J Cell Mol Med"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12944-019-1139-8","volume":"18","author":"Korani S.","year":"2019","unstructured":"Korani S.; Bahrami S.; Korani M.; Banach M.; Johnston T.P.; Sahebkar A.; Parenteral systems for statin delivery: a review. Lipids Health Dis 2019,18(1),193","journal-title":"Lipids Health Dis"},{"key":"ref=80","first-page":"1536","volume":"23","author":"Zidan A.S.","year":"2016","unstructured":"Zidan A.S.; Hosny K.M.; Ahmed O.A.A.; Fahmy U.A.; Assessment of simvastatin niosomes for pediatric transdermal drug delivery. Drug Deliv 2016,23(5),1536-1549","journal-title":"Drug Deliv"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.3390\/molecules24152685","volume":"24","author":"Tatham L.M.","year":"2019","unstructured":"Tatham L.M.; Liptrott N.J.; Rannard S.P.; Owen A.; Long-Acting Injectable Statins-Is It Time for a Paradigm Shift? Molecules 2019,24(15),2685","journal-title":"Molecules"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1208\/s12249-010-9381-4","volume":"11","author":"Shidhaye S.S.","year":"2010","unstructured":"Shidhaye S.S.; Thakkar P.V.; Dand N.M.; Kadam V.J.; Buccal drug delivery of pravastatin sodium. AAPS PharmSciTech 2010,11(1),416-424","journal-title":"AAPS PharmSciTech"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2147\/VHRM.S33664","volume":"8","author":"Phan B.A.","year":"2012","unstructured":"Phan B.A.; Dayspring T.D.; Toth P.P.; Ezetimibe therapy: mechanism of action and clinical update. Vasc Health Risk Manag 2012,8,415-427","journal-title":"Vasc Health Risk Manag"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jddst.2019.02.026","volume":"51","author":"Din F.","year":"2019","unstructured":"Din F.; ud; Zeb, A.; Shah, K. U.; Zia-ur-Rehman. Development, in-Vitro and in-Vivo Evaluation of Ezetimibe-Loaded Solid Lipid Nanoparticles and Their Comparison with Marketed Product. J Drug Deliv Sci Technol 2019,51,583-590","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jddst.2018.12.001","volume":"49","author":"Shukr M.H.","year":"2019","unstructured":"Shukr M.H.; Ismail S.; Ahmed S.M.; Development and Optimization of Ezetimibe Nanoparticles with Improved Antihyperlipidemic Activity. J Drug Deliv Sci Technol 2019,49,383-395","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1056\/NEJMp1508120","volume":"373","author":"Everett B.M.","year":"2015","unstructured":"Everett B.M.; Smith R.J.; Hiatt W.R.; Reducing LDL with PCSK9 Inhibitors--The Clinical Benefit of Lipid Drugs. N Engl J Med 2015,373(17),1588-1591","journal-title":"N Engl J Med"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"164","DOI":"10.18773\/austprescr.2016.060","volume":"39","author":"Page M.M.","year":"2016","unstructured":"Page M.M.; Watts G.F.; PCSK9 inhibitors - mechanisms of action. Aust Prescr 2016,39(5),164-167","journal-title":"Aust Prescr"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"76","DOI":"10.4330\/wjc.v9.i2.76","volume":"9","author":"Chaudhary R.","year":"2017","unstructured":"Chaudhary R.; Garg J.; Shah N.; Sumner A.; PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol 2017,9(2),76-91","journal-title":"World J Cardiol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1194\/jlr.R024794","volume":"53","author":"Porez G.","year":"2012","unstructured":"Porez G.; Prawitt J.; Gross B.; Staels B.; Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease. J Lipid Res 2012,53(9),1723-1737","journal-title":"J Lipid Res"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1097\/01.smj.0000208120.73327.db","volume":"99","author":"William I.","year":"2006","unstructured":"William I.; Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006,99(3),257-273","journal-title":"South Med J"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11892-009-0087-5","volume":"10","author":"Staels B.","year":"2010","unstructured":"Staels B.; Handelsman Y.; Fonseca V.; Bile acid sequestrants for lipid and glucose control. Curr Diab Rep 2010,10(1),70-77","journal-title":"Curr Diab Rep"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3389\/fphar.2018.01283","volume":"9","author":"Pavlovi\u0107 N.","year":"2018","unstructured":"Pavlovi\u0107 N.; Golo\u010dorbin-Kon S.; \u00d0ani\u0107 M.; Stanimirov B.; Al-Salami H.; Stankov K.; Mikov M.; Bile Acids and Their Derivatives as Potential Modifiers of Drug Release and Pharmacokinetic Profiles. Front Pharmacol 2018,9,1283","journal-title":"Front Pharmacol"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s12916-017-0787-7","volume":"15","author":"Sahebkar A.","year":"2017","unstructured":"Sahebkar A.; Simental-Mend\u00eda L.E.; Watts G.F.; Serban M-C.; Banach M.; Comparison of the effects of fibrates versus statins on plasma lipoprotein(a) concentrations: a systematic review and meta-analysis of head-to-head randomized controlled trials. BMC Med Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group2017,15(1),22","journal-title":"BMC Med"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"47","DOI":"10.4021\/cr270w","volume":"4","author":"Ling H.","year":"2013","unstructured":"Ling H.; Luoma J.T.; Hilleman D.; A Review of Currently Available Fenofibrate and Fenofibric Acid Formulations. Cardiol Res 2013,4(2),47-55","journal-title":"Cardiol Res"},{"key":"ref=95","doi-asserted-by":"publisher","DOI":"10.1111\/jfbc.12986","volume":"43","author":"Fern\u00e1ndez-Mart\u00ednez E.","year":"2019","unstructured":"Fern\u00e1ndez-Mart\u00ednez E.; Lira-Islas I.G.; Cari\u00f1o-Cort\u00e9s R.; Soria-Jasso L.E.; P\u00e9rez-Hern\u00e1ndez E.; P\u00e9rez-Hern\u00e1ndez N.; Dietary chia seeds (Salvia hispanica) improve acute dyslipidemia and steatohepatitis in rats. J Food Biochem 2019,43(9)","journal-title":"J Food Biochem"},{"key":"ref=96","unstructured":"IMPROVE-IT: Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin (Ezetimibe\/Simvastatin) vs Simvastatin (P04103)."},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.nut.2019.03.001","volume":"65","author":"Chen Q.","year":"2019","unstructured":"Chen Q.; Liu M.; Zhang P.; Fan S.; Huang J.; Yu S.; Zhang C.; Li H.; Fucoidan and galactooligosaccharides ameliorate high-fat diet-induced dyslipidemia in rats by modulating the gut microbiota and bile acid metabolism. Nutrition 2019,65,50-59","journal-title":"Nutrition"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1053\/j.gastro.2017.01.055","volume":"152","author":"Ch\u00e1vez-Talavera O.","year":"2017","unstructured":"Ch\u00e1vez-Talavera O.; Tailleux A.; Lefebvre P.; Staels B.; Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease. Gastroenterology 2017,152(7),1679-1694.e3","journal-title":"Gastroenterology"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.plipres.2009.11.001","volume":"49","author":"Fiorucci S.","year":"2010","unstructured":"Fiorucci S.; Cipriani S.; Baldelli F.; Mencarelli A.; Bile acid-activated receptors in the treatment of dyslipidemia and related disorders. Prog Lipid Res 2010,49(2),171-185","journal-title":"Prog Lipid Res"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1345\/aph.10263","volume":"35","author":"Aldridge M.A.","year":"2001","unstructured":"Aldridge M.A.; Ito M.K.; Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother 2001,35(7-8),898-907","journal-title":"Ann Pharmacother"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jff.2019.01.038","volume":"54","author":"Acharya P.","year":"2019","unstructured":"Acharya P.; Nanjaiah L.; Singh S.A.; Talahalli R.R.; Hyperglycemia Exacerbates Dyslipidemia-Induced Changes in Uptake, Synthesis, and Transporters of Bile Acids in Rats: Assessment of Restorative Potentials of ALA and EPA\u202f+\u202fDHA. J Funct Foods 2019,54(January),329-336","journal-title":"J Funct Foods"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.clinthera.2010.04.014","volume":"32","author":"Huijgen R.","year":"2010","unstructured":"Huijgen R.; Abbink E.J.; Bruckert E.; Stalenhoef A.F.H.; Imholz B.P.M.; Durrington P.N.; Trip M.D.; Eriksson M.; Visseren F.L.J.; Schaefer J.R.; Kastelein J.J.P.; Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther Triple Study Group2010,32(4),615-625","journal-title":"Clin Ther"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacl.2017.10.006","volume":"12","author":"Ishibashi S.","year":"2018","unstructured":"Ishibashi S.; Arai H.; Yokote K.; Araki E.; Suganami H.; Yamashita S.; Efficacy and safety of pemafibrate (K-877), a\u00a0selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol K-877 Study Group2018,12(1),173-184","journal-title":"J Clin Lipidol"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/B978-141605469-6.50030-5","author":"Jones P.H.","year":"2009","unstructured":"Jones P.H.;  Clinical Lipidology 2009,315-325","journal-title":"Clinical Lipidology"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1001\/jama.2011.353","volume":"305","author":"Jackevicius C.A.","year":"2011","unstructured":"Jackevicius C.A.; Tu J.V.; Ross J.S.; Ko D.T.; Carreon D.; Krumholz H.M.; Use of fibrates in the United States and Canada. JAMA 2011,305(12),1217-1224","journal-title":"JAMA"},{"key":"ref=106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009753","volume":"3","author":"Nordmann A.J.","year":"2012","unstructured":"Nordmann A.J.; Ferreira-Gonz\u00e1lez I.; Kasenda B.; Saccilotto R.; Bassler D.; Bhatnagar N.; Briel M.; Fibrates for primary prevention of cardiovascular disease events. Cochrane Database Syst Rev 2012,3(3)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/j.1552-4604.1991.tb01883.x","volume":"31","author":"Zimetbaum P.","year":"1991","unstructured":"Zimetbaum P.; Frishman W.H.; Kahn S.; Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins. J Clin Pharmacol 1991,31(1),25-37","journal-title":"J Clin Pharmacol"},{"key":"ref=108","first-page":"118","volume":"21","author":"Cavallero E.","year":"1995","unstructured":"Cavallero E.; Piolot A.; Jacotot B.; Postprandial lipoprotein clearance in type 2 diabetes: fenofibrate effects. Diabete Metab 1995,21(2),118-120","journal-title":"Diabete Metab"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1161\/CIRCULATIONAHA.107.181546","volume":"115","author":"Mosca L.","year":"2007","unstructured":"Mosca L.; Banka C.L.; Benjamin E.J.; Berra K.; Bushnell C.; Dolor R.J.; Ganiats T.G.; Gomes A.S.; Gornik H.L.; Gracia C.; Gulati M.; Haan C.K.; Judelson D.R.; Keenan N.; Kelepouris E.; Michos E.D.; Newby L.K.; Oparil S.; Ouyang P.; Oz M.C.; Petitti D.; Pinn V.W.; Redberg R.F.; Scott R.; Sherif K.; Smith S.C.; Sopko G.; Steinhorn R.H.; Stone N.J.; Taubert K.A.; Todd B.A.; Urbina E.; Wenger N.K.; Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation 2007,115(11),1481-1501","journal-title":"Circulation"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0002-9343(93)90113-4","volume":"94","author":"Miller M.","year":"1993","unstructured":"Miller M.; Bachorik P.S.; McCrindle B.W.; Kwiterovich P.O.; Effect of gemfibrozil in men with primary isolated low high-density lipoprotein cholesterol: a randomized, double-blind, placebo-controlled, crossover study. Am J Med 1993,94(1),7-12","journal-title":"Am J Med"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1001\/archinte.161.11.1379","volume":"161","author":"Grundy S.M.","year":"2001","unstructured":"Grundy S.M.; Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. Arch Intern Med 2001,161(11),1379-1380","journal-title":"Arch Intern Med"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jacl.2008.06.013","volume":"2","author":"Blaha M.J.","year":"2008","unstructured":"Blaha M.J.; Blumenthal R.S.; Brinton E.A.; Jacobson T.A.; The importance of non-HDL cholesterol reporting in lipid management. J Clin Lipidol National Lipid Association Taskforce on Non-HDL Cholesterol2008,2(4),267-273","journal-title":"J Clin Lipidol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/CRD.0b013e31816b43d3","volume":"16","author":"Remick J.","year":"2008","unstructured":"Remick J.; Weintraub H.; Setton R.; Offenbacher J.; Fisher E.; Schwartzbard A.; Fibrate therapy: an update. Cardiol Rev 2008,16(3),129-141","journal-title":"Cardiol Rev"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1185\/030079902125000516","volume":"18","author":"Elisaf M.","year":"2002","unstructured":"Elisaf M.; Effects of fibrates on serum metabolic parameters. Curr Med Res Opin 2002,18(5),269-276","journal-title":"Curr Med Res Opin"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","volume":"127","author":"Tavori H.","year":"2013","unstructured":"Tavori H.; Fan D.; Blakemore J.L.; Yancey P.G.; Ding L.; Linton M.F.; Fazio S.; Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation. Circulation 2013,127(24),2403-2413","journal-title":"Circulation"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1210\/jc.2017-00684","volume":"102","author":"Ooi T.C.","year":"2017","unstructured":"Ooi T.C.; Krysa J.A.; Chaker S.; Abujrad H.; Mayne J.; Henry K.; Cousins M.; Raymond A.; Favreau C.; Taljaard M.; Chr\u00e9tien M.; Mbikay M.; Proctor S.D.; Vine D.F.; The Effect of PCSK9 Loss-of-Function Variants on the Postprandial Lipid and ApoB-Lipoprotein Response. J Clin Endocrinol Metab 2017,102(9),3452-3460","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.116.025253","volume":"135","author":"Reyes-Soffer G.","year":"2017","unstructured":"Reyes-Soffer G.; Pavlyha M.; Ngai C.; Thomas T.; Holleran S.; Ramakrishnan R.; Karmally W.; Nandakumar R.; Fontanez N.; Obunike J.; Marcovina S.M.; Lichtenstein A.H.; Matthan N.R.; Matta J.; Maroccia M.; Becue F.; Poitiers F.; Swanson B.; Cowan L.; Sasiela W.J.; Surks H.K.; Ginsberg H.N.; Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy Humans. Circulation 2017,135(4),352-362","journal-title":"Circulation"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1093\/eurheartj\/ehy122","volume":"39","author":"Watts G.F.","year":"2018","unstructured":"Watts G.F.; Chan D.C.; Somaratne R.; Wasserman S.M.; Scott R.; Marcovina S.M.; Barrett P.H.R.; Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics. Eur Heart J 2018,39(27),2577-2585","journal-title":"Eur Heart J"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"e673","DOI":"10.1161\/CIR.0000000000000709","volume":"140","author":"Skulas-Ray A.C.","year":"2019","unstructured":"Skulas-Ray A.C.; Wilson P.W.F.; Harris W.S.; Brinton E.A.; Kris-Etherton P.M.; Richter C.K.; Jacobson T.A.; Engler M.B.; Miller M.; Robinson J.G.; Blum C.B.; Rodriguez-Leyva D.; de Ferranti S.D.; Welty F.K.; Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association. Circulation American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology2019,140(12),e673-e691","journal-title":"Circulation"},{"key":"ref=120","first-page":"87","volume":"33","author":"Vecka M.","year":"2012","unstructured":"Vecka M.; Du\u0161ejovsk\u00e1 M.; Stankova B.; Zeman M.; Vavrova L.; Kodydkova J.; Slaby A.; Zak A.; N-3 polyunsaturated fatty acids in the treatment of atherogenic dyslipidemia. Neuroendocrinol Lett 2012,33(Suppl. 2),87-92","journal-title":"Neuroendocrinol Lett"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","volume":"8","author":"Kastelein J.J.P.","year":"2014","unstructured":"Kastelein J.J.P.; Maki K.C.; Susekov A.; Ezhov M.; Nordestgaard B.G.; Machielse B.N.; Kling D.; Davidson M.H.; Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol 2014,8(1),94-106","journal-title":"J Clin Lipidol"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/clc.23055","volume":"41","author":"Nicholls S.J.","year":"2018","unstructured":"Nicholls S.J.; Lincoff A.M.; Bash D.; Ballantyne C.M.; Barter P.J.; Davidson M.H.; Kastelein J.J.P.; Koenig W.; McGuire D.K.; Mozaffarian D.; Pedersen T.R.; Ridker P.M.; Ray K.; Karlson B.W.; Lundstr\u00f6m T.; Wolski K.; Nissen S.E.; Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial. Clin Cardiol 2018,41(10),1281-1288","journal-title":"Clin Cardiol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"4416","DOI":"10.3390\/nu7064416","volume":"7","author":"Ooi E.M.M.","year":"2015","unstructured":"Ooi E.M.M.; Watts G.F.; Ng T.W.K.; Barrett P.H.R.; Effect of dietary Fatty acids on human lipoprotein metabolism: a comprehensive update. Nutrients 2015,7(6),4416-4425","journal-title":"Nutrients"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3390\/nu11061299","volume":"11","author":"Desmarchelier C.","year":"2019","unstructured":"Desmarchelier C.; Borel P.; Lairon D.; Maraninchi M.; Val\u00e9ro R.; Effect of Nutrient and Micronutrient Intake on Chylomicron Production and Postprandial Lipemia. Nutrients 2019,11(6),1299","journal-title":"Nutrients"},{"key":"ref=125","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2019.06.880","volume":"287","author":"Rizos E.","year":"2019","unstructured":"Rizos E.; Markozannes G.; Tsapas A.; Ntzani E.; Omega-3 Supplementation And Cardiovascular Disease: Meta-Analysis With Trial Sequential Analysis. Atherosclerosis 2019,287","journal-title":"Atherosclerosis"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/jnci\/djt174","volume":"105","author":"Brasky T.M.","year":"2013","unstructured":"Brasky T.M.; Darke A.K.; Song X.; Tangen C.M.; Goodman P.J.; Thompson I.M.; Meyskens F.L.; Goodman G.E.; Minasian L.M.; Parnes H.L.; Klein E.A.; Kristal A.R.; Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. J Natl Cancer Inst 2013,105(15),1132-1141","journal-title":"J Natl Cancer Inst"},{"key":"ref=127","volume":"7","author":"Abdelhamid A.S.","year":"2018","unstructured":"Abdelhamid A.S.; Brown T.J.; Brainard J.S.; Biswas P.; Thorpe G.C.; Moore H.J.; Deane K.H.; AlAbdulghafoor F.K.; Summerbell C.D.; Worthington H.V.; Song F.; Hooper L.; Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2018,7(7)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"20B","DOI":"10.1016\/j.amjcard.2008.02.029","volume":"101","author":"Kamanna V.S.","year":"2008","unstructured":"Kamanna V.S.; Kashyap M.L.; Mechanism of action of niacin. Am J Cardiol 2008,101(8A),20B-26B","journal-title":"Am J Cardiol"},{"key":"ref=129","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.81725","author":"Keenan M.","year":"2019","unstructured":"Keenan M.;  Dyslipidemia 2019","journal-title":"Dyslipidemia"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"753.e13","DOI":"10.1016\/j.amjmed.2016.02.039","volume":"129","author":"Goldberg R.B.","year":"2016","unstructured":"Goldberg R.B.; Bittner V.A.; Dunbar R.L.; Fleg J.L.; Grunberger G.; Guyton J.R.; Leiter L.A.; McBride R.; Robinson J.G.; Simmons D.L.; Wysham C.; Xu P.; Boden W.E.; Effects of Extended-Release Niacin Added to Simvastatin\/Ezetimibe on Glucose and Insulin Values in AIM-HIGH. Am J Med 2016,129(7),753.e13-753.e22","journal-title":"Am J Med"},{"key":"ref=131","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0077049","volume":"8","author":"Li C.","year":"2013","unstructured":"Li C.; Zhang W.; Zhou F.; Chen C.; Zhou L.; Li Y.; Liu L.; Pei F.; Luo H.; Hu Z.; Cai J.; Zeng C.; Cholesteryl ester transfer protein inhibitors in the treatment of dyslipidemia: a systematic review and meta-analysis. PLoS One 2013,8(10)","journal-title":"PLoS One"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1001\/jama.2017.11467","volume":"318","author":"Ference B.A.","year":"2017","unstructured":"Ference B.A.; Kastelein J.J.P.; Ginsberg H.N.; Chapman M.J.; Nicholls S.J.; Ray K.K.; Packard C.J.; Laufs U.; Brook R.D.; Oliver-Williams C.; Butterworth A.S.; Danesh J.; Smith G.D.; Catapano A.L.; Sabatine M.S.; Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk. JAMA 2017,318(10),947-956","journal-title":"JAMA"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","volume":"377","author":"Bowman L.","year":"2017","unstructured":"Bowman L.; Hopewell J.C.; Chen F.; Wallendszus K.; Stevens W.; Collins R.; Wiviott S.D.; Cannon C.P.; Braunwald E.; Sammons E.; Landray M.J.; Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease. N Engl J Med HPS3\/TIMI55\u2013REVEAL Collaborative Group2017,377(13),1217-1227","journal-title":"N Engl J Med"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.jacc.2018.10.072","volume":"73","author":"Armitage J.","year":"2019","unstructured":"Armitage J.; Holmes M.V.; Preiss D.; Cholesteryl Ester Transfer\u00a0Protein Inhibition for Preventing Cardiovascular\u00a0Events: JACC Review Topic of the Week. J Am Coll Cardiol 2019,73(4),477-487","journal-title":"J Am Coll Cardiol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1161\/CIRCRESAHA.111.300576","volume":"112","author":"Majmudar M.D.","year":"2013","unstructured":"Majmudar M.D.; Yoo J.; Keliher E.J.; Truelove J.J.; Iwamoto Y.; Sena B.; Dutta P.; Borodovsky A.; Fitzgerald K.; Di Carli M.F.; Libby P.; Anderson D.G.; Swirski F.K.; Weissleder R.; Nahrendorf M.; Polymeric nanoparticle PET\/MR imaging allows macrophage detection in atherosclerotic plaques. Circ Res 2013,112(5),755-761","journal-title":"Circ Res"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2217\/nnm.15.26","volume":"10","author":"Palekar R.U.","year":"2015","unstructured":"Palekar R.U.; Jallouk A.P.; Lanza G.M.; Pan H.; Wickline S.A.; Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine (Lond) 2015,10(11),1817-1832","journal-title":"Nanomedicine (Lond)"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"4710","DOI":"10.7150\/thno.26284","volume":"8","author":"Bejarano J.","year":"2018","unstructured":"Bejarano J.; Navarro-Marquez M.; Morales-Zavala F.; Morales J.O.; Garcia-Carvajal I.; Araya-Fuentes E.; Flores Y.; Verdejo H.E.; Castro P.F.; Lavandero S.; Kogan M.J.; Nanoparticles for diagnosis and therapy of atherosclerosis and myocardial infarction: evolution toward prospective theranostic approaches. Theranostics 2018,8(17),4710-4732","journal-title":"Theranostics"},{"key":"ref=138","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181668","volume":"12","author":"Alkhalil M.","year":"2017","unstructured":"Alkhalil M.; Biasiolli L.; Chai J.T.; Galassi F.; Li L.; Darby C.; Halliday A.; Hands L.; Magee T.; Perkins J.; Sideso E.; Jezzard P.; Robson M.D.; Handa A.; Choudhury R.P.; Quantification of carotid plaque lipid content with magnetic resonance T2 mapping in patients undergoing carotid endarterectomy. PLoS One 2017,12(7)","journal-title":"PLoS One"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s40005-017-0353-5","volume":"48","author":"Yang S.","year":"2018","unstructured":"Yang S.; Moon Y-A.; Current Drugs, Targets, and Drug Delivery Systems for the Treatment of Dyslipidemia. J Pharm Investig 2018,48(3),233-241","journal-title":"J Pharm Investig"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3390\/diseases6030063","volume":"6","author":"Kosmas C.E.","year":"2018","unstructured":"Kosmas C.E.; Mu\u00f1oz Estrella A.; Sourlas A.; Silverio D.; Hilario E.; Montan P.D.; Guzman E.; Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. Diseases 2018,6(3),63","journal-title":"Diseases"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"Ray K.K.","year":"2017","unstructured":"Ray K.K.; Landmesser U.; Leiter L.A.; Kallend D.; Dufour R.; Karakas M.; Hall T.; Troquay R.P.T.; Turner T.; Visseren F.L.J.; Wijngaard P.; Wright R.S.; Kastelein J.J.P.; Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol. N Engl J Med 2017,376(15),1430-1440","journal-title":"N Engl J Med"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"m139","DOI":"10.1136\/bmj.m139","volume":"368","author":"Iacobucci G.","year":"2020","unstructured":"Iacobucci G.; Inclisiran: UK to roll out new cholesterol lowering drug from next year. BMJ 2020,368,m139","journal-title":"BMJ"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.jjcc.2017.10.017","volume":"71","author":"Bandyopadhyay D.","year":"2018","unstructured":"Bandyopadhyay D.; Hajra A.; Ashish K.; Qureshi A.; Ball S.; New hope for hyperlipidemia management: Inclisiran. J Cardiol 2018,71(5),523-524","journal-title":"J Cardiol"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1609243","volume":"376","author":"Fitzgerald K.","year":"2017","unstructured":"Fitzgerald K.; White S.; Borodovsky A.; Bettencourt B.R.; Strahs A.; Clausen V.; Wijngaard P.; Horton J.D.; Taubel J.; Brooks A.; Fernando C.; Kauffman R.S.; Kallend D.; Vaishnaw A.; Simon A.; A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med 2017,376(1),41-51","journal-title":"N Engl J Med"},{"key":"ref=145","unstructured":"Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (ORION-10) NCT03399370Available at:","journal-title":"Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol (ORION-10)"},{"key":"ref=146","unstructured":"Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11) NCT03400800Available at:","journal-title":"Inclisiran for Subjects With ACSVD or ACSVD-Risk Equivalents and Elevated Low-density Lipoprotein Cholesterol (ORION-11)"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.nut.2018.06.015","volume":"58","author":"Simental-Mend\u00eda L.E.","year":"2019","unstructured":"Simental-Mend\u00eda L.E.; Guerrero-Romero F.; Effect of resveratrol supplementation on lipid profile in subjects with dyslipidemia: A randomized double-blind, placebo-controlled trial. Nutrition 2019,58,7-10","journal-title":"Nutrition"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.nut.2019.03.004","volume":"65","author":"Gomes A.P.O.","year":"2019","unstructured":"Gomes A.P.O.; Ferreira M.A.; Camargo J.M.; Ara\u00fajo M.O.; Mortoza A.S.; Mota J.F.; Coelho A.S.G.; Capitani C.D.; Coltro W.K.T.; Botelho P.B.; Organic beet leaves and stalk juice attenuates HDL-C reduction induced by high-fat meal in dyslipidemic patients: A pilot randomized controlled trial. Nutrition 2019,65,68-73","journal-title":"Nutrition"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"S123","DOI":"10.1016\/j.freeradbiomed.2018.04.406","volume":"120","author":"Barcelos de Castro A.P.R.","year":"2018","unstructured":"Barcelos de Castro A.P.R.; Antunes de Moraes A.E.; Simabuco F.M.; Massa G.O.; Corona L.P.; Bezerra R.M.N.; Beetroot Leaves (Beta Vulgaris L.) Assist in Cholesterol Reduction in Dyslipidemic Obese Adults. Free Radic Biol Med 2018,120((Suppl. 1)),S123","journal-title":"Free Radic Biol Med"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"497","DOI":"10.3390\/nu11030497","volume":"11","author":"Caro-G\u00f3mez E.","year":"2019","unstructured":"Caro-G\u00f3mez E.; Sierra J.A.; Escobar J.S.; \u00c1lvarez-Quintero R.; Naranjo M.; Medina S.; Vel\u00e1squez-Mej\u00eda E.P.; Tabares-Guevara J.H.; Jaramillo J.C.; Le\u00f3n-Varela Y.M.; Mu\u00f1oz-Durango K.; Ram\u00edrez-Pineda J.R.; Green Coffee Extract Improves Cardiometabolic Parameters and Modulates Gut Microbiota in High-Fat-Diet-Fed ApoE Mice. Nutrients 2019,11(3),497","journal-title":"Nutrients"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.eujim.2019.05.001","volume":"28","author":"Salamat S.","year":"2019","unstructured":"Salamat S.; Sharif S.S.; Nazary-Vanani A.; Kord-Varkaneh H.; Clark C.C.T.; Mohammadshahi M.; The Effect of Green Coffee Extract Supplementation on Serum Oxidized LDL Cholesterol and Total Antioxidant Capacity in Patients with Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Trial. Eur J Integr Med 2019,28,109-113","journal-title":"Eur J Integr Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.numecd.2019.07.012","volume":"29","author":"Askarpour M.","year":"2019","unstructured":"Askarpour M.; Hadi A.; Symonds M.E.; Miraghajani M.; Sadeghi O.; Sheikhi A.; Ghaedi E.; Efficacy of l-carnitine supplementation for management of blood lipids: A systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis 2019,29(11),1151-1167","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.cbi.2018.10.010","volume":"297","author":"Youssef D.A.","year":"2019","unstructured":"Youssef D.A.; El-Fayoumi H.M.; Mahmoud M.F.; Beta-caryophyllene protects against diet-induced dyslipidemia and vascular inflammation in rats: Involvement of CB2 and PPAR-\u03b3 receptors. Chem Biol Interact 2019,297,16-24","journal-title":"Chem Biol Interact"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jff.2018.10.032","volume":"52","author":"Mendoza-S\u00e1nchez M.","year":"2019","unstructured":"Mendoza-S\u00e1nchez M.; P\u00e9rez-Ram\u00edrez I.F.; Wall-Medrano A.; Martinez-Gonzalez A.I.; Gallegos-Corona M.A.; Reynoso-Camacho R.; Chemically Induced Common Bean (Phaseolus Vulgaris L.) Sprouts Ameliorate Dyslipidemia by Lipid Intestinal Absorption Inhibition. J Funct Foods 2019,52,54-62","journal-title":"J Funct Foods"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1089\/jmf.2019.0088","volume":"23","author":"Bertuccioli A.","year":"2020","unstructured":"Bertuccioli A.; Moricoli S.; Amatori S.; Rocchi M.B.L.; Vici G.; Sisti D.; Berberine and Dyslipidemia: Different Applications and Biopharmaceutical Formulations Without Statin-Like Molecules-A Meta-Analysis. J Med Food 2020,23(2),101-113","journal-title":"J Med Food"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"365742","DOI":"10.1155\/2014\/365742","volume":"2014","author":"Hu M.","year":"2014","unstructured":"Hu M.; Zeng W.; Tomlinson B.; Evaluation of a Crataegus -Based Multiherb Formula for Dyslipidemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Evidence-Based Complement. Altern Med 2014,2014,365742-365742","journal-title":"Altern Med"},{"key":"ref=157","first-page":"1","volume":"2","author":"Romo-araiza A.","year":"2018","unstructured":"Romo-araiza A.; R\u00edos-hoyo A.; Ibarra A.; Hern\u00e1ndez-ortega M.; Meneses-mayo M.; Effect of a Formulation with Nopal (Opuntia Ficus Indica), Amaranth (Amaranthus Cruentus) and Mushroom (Pleurotus Ostreatus) in a Murine Model of Diet-Induced Cardiometabolic Disruptions. Insights Nutr Metab 2018,2(1),1-13","journal-title":"Insights Nutr Metab"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2016.02.029","volume":"249","author":"Ishibashi S.","year":"2016","unstructured":"Ishibashi S.; Yamashita S.; Arai H.; Araki E.; Yokote K.; Suganami H.; Fruchart J-C.; Kodama T.; Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis K-877-04 Study Group2016,249,36-43","journal-title":"Atherosclerosis"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(07)60527-3","volume":"369","author":"Yokoyama M.","year":"2007","unstructured":"Yokoyama M.; Origasa H.; Matsuzaki M.; Matsuzawa Y.; Saito Y.; Ishikawa Y.; Oikawa S.; Sasaki J.; Hishida H.; Itakura H.; Kita T.; Kitabatake A.; Nakaya N.; Sakata T.; Shimada K.; Shirato K.; Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet Japan EPA lipid intervention study (JELIS) Investigators2007,369(9567),1090-1098","journal-title":"Lancet"},{"key":"ref=160","unstructured":"A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High Risk Patients With Hypertriglyceridemia and on Statin The Primary Objective is to Evaluate the Effect of 4 g\/Day AMR101 for Preventing the Occurrence of a First Major cardiovascular event NCT01492361","journal-title":"The Primary Objective is to Evaluate the Effect of 4 g\/Day AMR101 for Preventing the Occurrence of a First Major cardiovascular event"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"Bhatt D.L.","year":"2019","unstructured":"Bhatt D.L.; Steg P.G.; Miller M.; Brinton E.A.; Jacobson T.A.; Ketchum S.B.; Doyle R.T.; Juliano R.A.; Jiao L.; Granowitz C.; Tardif J-C.; Ballantyne C.M.; Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med REDUCE-IT Investigators2019,380(1),11-22","journal-title":"N Engl J Med"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1056\/NEJMoa1203859","volume":"367","author":"Bosch J.","year":"2012","unstructured":"Bosch J.; Gerstein H.C.; Dagenais G.R.; D\u00edaz R.; Dyal L.; Jung H.; Maggiono A.P.; Probstfield J.; Ramachandran A.; Riddle M.C.; Ryd\u00e9n L.E.; Yusuf S.; n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med ORIGIN Trial Investigators2012,367(4),309-318","journal-title":"N Engl J Med"},{"key":"ref=163","unstructured":"The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) (ORIGIN) NCT00069784Available at:"},{"key":"ref=164","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12944-015-0049-7","volume":"14","author":"Leslie M.A.","year":"2015","unstructured":"Leslie M.A.; Cohen D.J.A.; Liddle D.M.; Robinson L.E.; Ma D.W.L.; A review of the effect of omega-3 polyunsaturated fatty acids on blood triacylglycerol levels in normolipidemic and borderline hyperlipidemic individuals. Lipids Health Dis 2015,14(1),53","journal-title":"Lipids Health Dis"},{"key":"ref=165","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2019.107494","volume":"34","author":"Saraswathi V.","year":"2020","unstructured":"Saraswathi V.; Heineman R.; Alnouti Y.; Shivaswamy V.; Desouza C.V.; A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. J Diabetes Complications 2020,34(2)","journal-title":"J Diabetes Complications"},{"key":"ref=166","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11789-017-0089-9","volume":"12","author":"Schettler V.J.J.","year":"2017","unstructured":"Schettler V.J.J.; Neumann C.L.; Peter C.; Zimmermann T.; Julius U.; Roeseler E.; Heigl F.; Gr\u00fctzmacher P.; Blume H.; Vogt A.; The German Lipoprotein Apheresis Registry (GLAR) - almost 5\u00a0years on. Clin Res Cardiol Suppl Scientific Board of GLAR for the German Apheresis Working Group2017,12(S1)(Suppl. 1),44-49","journal-title":"Clin Res Cardiol Suppl"},{"key":"ref=167","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","volume":"388","author":"Viney N.J.","year":"2016","unstructured":"Viney N.J.; van Capelleveen J.C.; Geary R.S.; Xia S.; Tami J.A.; Yu R.Z.; Marcovina S.M.; Hughes S.G.; Graham M.J.; Crooke R.M.; Crooke S.T.; Witztum J.L.; Stroes E.S.; Tsimikas S.; Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016,388(10057),2239-2253","journal-title":"Lancet"},{"key":"ref=168","unstructured":"Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Patients With Hyperlipoproteinemia(a) and Cardiovascular Disease NCT03070782Available at:"},{"key":"ref=169","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s11789-019-00096-2","volume":"14","author":"Vogt A.","year":"2019","unstructured":"Vogt A.; Lipoprotein(a)-antisense therapy. Clin Res Cardiol Suppl 2019,14(S1)(Suppl. 1),51-56","journal-title":"Clin Res Cardiol Suppl"},{"key":"ref=170","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1056\/NEJMoa1803917","volume":"380","author":"Ray K.K.","year":"2019","unstructured":"Ray K.K.; Bays H.E.; Catapano A.L.; Lalwani N.D.; Bloedon L.T.; Sterling L.R.; Robinson P.L.; Ballantyne C.M.; Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol. N Engl J Med CLEAR Harmony Trial2019,380(11),1022-1032","journal-title":"N Engl J Med"},{"key":"ref=171","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1001\/jama.2019.16585","volume":"322","author":"Goldberg A.C.","year":"2019","unstructured":"Goldberg A.C.; Leiter L.A.; Stroes E.S.G.; Baum S.J.; Hanselman J.C.; Bloedon L.T.; Lalwani N.D.; Patel P.M.; Zhao X.; Duell P.B.; Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial. JAMA 2019,322(18),1780-1788","journal-title":"JAMA"},{"key":"ref=172","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3390\/ijms17091440","volume":"17","author":"Siafaka P.I.","year":"2016","unstructured":"Siafaka P.I.; \u00dcst\u00fcnda\u011f Okur N.; Karavas E.; Bikiaris D.N.; Surface Modified Multifunctional and Stimuli Responsive Nanoparticles for Drug Targeting: Current Status and Uses. Int J Mol Sci 2016,17(9),1440","journal-title":"Int J Mol Sci"},{"key":"ref=173","doi-asserted-by":"publisher","first-page":"109366","DOI":"10.1016\/j.eurpolymj.2019.109366","volume":"122","author":"Sarangi B.","year":"2020","unstructured":"Sarangi B.; Mishra K.; Mohanta G.P.; Manna P.K.; \nIn Vitro in Vivo Correlation (IVIVC) of Solid Lipid Nanoparticles Loaded with Poorly Water-Soluble Drug Lovastatin. Eur Polym J 2020,122(1),109366","journal-title":"Eur Polym J"},{"key":"ref=174","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejps.2016.03.021","volume":"88","author":"Siafaka P.I.","year":"2016","unstructured":"Siafaka P.I.; Barmbalexis P.; Bikiaris D.N.; Novel electrospun nanofibrous matrices prepared from poly(lactic acid)\/poly(butylene adipate) blends for controlled release formulations of an anti-rheumatoid agent. Eur J Pharm Sci 2016,88,12-25","journal-title":"Eur J Pharm Sci"},{"key":"ref=175","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3390\/ijms17030282","volume":"17","author":"Siafaka P.I.","year":"2016","unstructured":"Siafaka P.I.; \u00dcst\u00fcnda\u011f Okur N.; Mone M.; Giannakopoulou S.; Er S.; Pavlidou E.; Karavas E.; Bikiaris D.N.; Two Different Approaches for Oral Administration of Voriconazole Loaded Formulations: Electrospun Fibers versus \u03b2-Cyclodextrin Complexes. Int J Mol Sci 2016,17(3),282","journal-title":"Int J Mol Sci"},{"key":"ref=176","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118809","volume":"573","author":"Kajdi\u010d S.","year":"2020","unstructured":"Kajdi\u010d S.; Zupan\u010di\u010d \u0160.; Ro\u0161kar R.; Kocbek P.; The potential of nanofibers to increase solubility and dissolution rate of the poorly soluble and chemically unstable drug lovastatin. Int J Pharm 2020,573","journal-title":"Int J Pharm"},{"key":"ref=177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jddst.2019.101342","volume":"55","author":"Al-Shdefat R.","year":"2020","unstructured":"Al-Shdefat R.; Anwer M.K.; Fayed M.H.; Alsulays B.B.; Tawfeek H.M.; Abdel-Rahman R.F.; Soliman G.A.; Preparation and Evaluation of Spray Dried Rosuvastatin Calcium-PVP Microparticles for the Improvement of Serum Lipid Profile. J Drug Deliv Sci Technol 2020,55","journal-title":"J Drug Deliv Sci Technol"},{"key":"ref=178","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ijpharm.2019.02.002","volume":"560","author":"Rizvi S.Z.H.","year":"2019","unstructured":"Rizvi S.Z.H.; Shah F.A.; Khan N.; Muhammad I.; Ali K.H.; Ansari M.M.; Din F.U.; Qureshi O.S.; Kim K.W.; Choe Y.H.; Kim J.K.; Zeb A.; Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model. Int J Pharm 2019,560,136-143","journal-title":"Int J Pharm"},{"key":"ref=179","doi-asserted-by":"publisher","DOI":"10.1016\/j.molstruc.2019.127296","volume":"1202","author":"Sayadi K.","year":"2020","unstructured":"Sayadi K.; Rahdar A.; Hajinezhad M.R.; Nikazar S.; Susan M.A.B.H.; Atorvastatin-Loaded SBA-16 Nanostructures: Synthesis, Physical Characterization, and Biochemical Alterations in Hyperlipidemic Rats. J Mol Struct 2020,1202","journal-title":"J Mol Struct"},{"key":"ref=180","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2019.118891","volume":"574","author":"Shaker M.A.","year":"2020","unstructured":"Shaker M.A.; Elbadawy H.M.; Shaker M.A.; Improved solubility, dissolution, and oral bioavailability for atorvastatin-Pluronic\u00ae solid dispersions. Int J Pharm 2020,574","journal-title":"Int J Pharm"},{"key":"ref=181","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1016\/j.bmc.2019.04.019","volume":"27","author":"Zhang Y.","year":"2019","unstructured":"Zhang Y.; Zhang X.; Zeng C.; Li B.; Zhang C.; Li W.; Hou X.; Dong Y.; Targeted delivery of atorvastatin via asialoglycoprotein receptor (ASGPR). Bioorg Med Chem 2019,27(11),2187-2191","journal-title":"Bioorg Med Chem"},{"key":"ref=182","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.2174\/13816128113199990314","volume":"19","author":"Katsiki N.","year":"2013","unstructured":"Katsiki N.; Theocharidou E.; Karagiannis A.; Athyros V.G.; Mikhailidis D.P.; Ezetimibe therapy for dyslipidemia: an update. Curr Pharm Des 2013,19(17),3107-3114","journal-title":"Curr Pharm Des"},{"key":"ref=183","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.3389\/fphar.2018.01219","volume":"9","author":"Alshamsan A.","year":"2018","unstructured":"Alshamsan A.; Kazi M.; Badran M.M.; Alanazi F.K.; Role of Alternative Lipid Excipients in the Design of Self-Nanoemulsifying Formulations for Fenofibrate: Characterization, in vitro Dispersion, Digestion and ex vivo Gut Permeation Studies. Front Pharmacol 2018,9,1219","journal-title":"Front Pharmacol"},{"key":"ref=184","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3390\/ph12030109","volume":"12","author":"Kevadiya B.D.","year":"2019","unstructured":"Kevadiya B.D.; Chen L.; Zhang L.; Thomas M.B.; Dav\u00e9 R.N.; Fenofibrate Nanocrystal Composite Microparticles for Intestine-Specific Oral Drug Delivery System. Pharmaceuticals (Basel) 2019,12(3),109","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=185","doi-asserted-by":"publisher","first-page":"420","DOI":"10.4172\/pharmaceutical-sciences.1000374","volume":"80","author":"Shelake S.","year":"2018","unstructured":"Shelake S.; Patil, S. V; Sangave, P. Formulation and Evaluation of Fenofibrate-Loaded Nanoparticles by Precipitation Method. Indian J Pharm Sci 2018,80(3),420-427","journal-title":"Indian J Pharm Sci"},{"key":"ref=186","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12944-019-1096-2","volume":"18","author":"Yuan C.","year":"2019","unstructured":"Yuan C.; Zhang X.; Long X.; Jin J.; Jin R.; Effect of \u03b2-sitosterol self-microemulsion and \u03b2-sitosterol ester with linoleic acid on lipid-lowering in hyperlipidemic mice. Lipids Health Dis 2019,18(1),157","journal-title":"Lipids Health Dis"}],"container-title":["Endocrine, Metabolic &amp; Immune Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184743","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/184743\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download\/184743","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T06:40:50Z","timestamp":1648449650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/184743\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":186,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871530320666200810144004","relation":{},"ISSN":["1871-5303"],"issn-type":[{"value":"1871-5303","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}